Bright Minds Biosciences files as a foreign issuer, and its SEC reports document clinical-stage biotechnology operations, capital formation and public-company governance. Form 6-K reports include interim condensed consolidated financial statements, management's discussion and analysis, executive certifications, material-event releases and exhibits incorporated by reference into Form F-3 registration statements.
The filings cover capital-structure disclosures for common shares, shelf registrations, public offerings and equity distribution arrangements, as well as clinical and regulatory updates for the company's 5-HT receptor agonist pipeline, including BMB-101. They also record operating and financial results, material agreements and shareholder voting matters tied to development-stage CNS drug programs.
BRIGHT MINDS BIOSCIENCES INC. Schedule 13G discloses that Vestal Point Capital and Ryan Wilder report beneficial ownership of 492,319 shares of Common Shares, representing 5% of the class. The percentage is calculated using 9,787,161 Common Shares outstanding as of February 12, 2026 as stated in the filing. The filing shows shared voting and shared dispositive power over the reported shares and states the shares are held on behalf of the Vestal Point Fund and Account.
Janus Henderson Group plc amended a Schedule 13G to report beneficial ownership of 1,284,324 shares of Bright Minds Biosciences Inc. (CUSIP 10919W405), representing 13.1% of the class as of 03/31/2026. The filing states the shares are held in multiple managed portfolios for which Janus Henderson is ultimate parent; the Asset Managers exercise shared voting and dispositive power over 1,284,324 shares but disclaim rights to dividends or sale proceeds. The disclosure names Janus Henderson Biotech Innovation Master Fund Ltd. as a managed portfolio holding more than 5% and notes an irrevocable delegation of investment and voting discretion affecting reporting status. The filing is signed by a compliance officer on 5/15/2026.
Janus Henderson Group plc amended a Schedule 13G to report beneficial ownership of 1,284,324 shares of Bright Minds Biosciences Inc. representing 13.1% of the class. The filing states the Asset Managers have shared voting and shared dispositive power over these shares and that the Managed Portfolios hold rights to dividends and sale proceeds. The filing identifies Janus Henderson Biotech Innovation Master Fund Ltd. as a Managed Portfolio holding more than 5% and notes an irrevocable delegation of investment and voting discretion affecting reporting status. The Schedule is signed by Kristin Mariani on 5/15/2026.
Bright Minds Biosciences Inc. ownership update: Vivo Opportunity entities amended beneficial ownership reporting to show combined holdings of certain Vivo funds and general partners. Vivo Opportunity Fund Holdings, L.P. (via Vivo Opportunity, LLC) holds 504,645 shares of Common Stock, representing 5.2% of the class. Vivo Opportunity Cayman Fund, L.P. (via Vivo Opportunity Cayman, LLC) holds 52,527 shares, representing 0.5%. The filing cites 9,787,161 shares outstanding as of February 12, 2026. All reported shares are held of record by the named partnership entities and voting and dispositive powers are stated as sole for each reported amount.
Bright Minds Biosciences Inc. Schedule 13G/A shows Cormorant Asset Management, LP and Bihua Chen report shared beneficial ownership of 950,000 common shares, representing 9.71% of the class. The filing states 9,787,161 Common Shares outstanding as of February 12, 2026. The shares are held through Cormorant Global Healthcare Master Fund, LP and reported as shared voting and dispositive power.
Cormorant Global Healthcare Master Fund, LP, an entity associated with Cormorant Asset Management and Bihua Chen, reported an open-market sale of 109,331 common shares of Bright Minds Biosciences Inc. at $89.50 per share.
After this transaction, the reporting structure shows 950,000 common shares indirectly held. The reporting persons, including Cormorant Asset Management and Bihua Chen, disclaim beneficial ownership of the reported shares except to the extent of their pecuniary interest.
Janus Henderson Group plc filed an amended Schedule 13G/A reporting beneficial ownership of 1,155,995 shares of Bright Minds Biosciences Inc. common stock, or 14.9% of the class, as of 12/31/2025.
The shares are held across various Janus Henderson asset management subsidiaries in managed client accounts, with Janus Henderson reporting shared power to vote and dispose of all 1,155,995 shares and no sole voting or dispositive power. The filing states the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Bright Minds Biosciences.
Bright Minds Biosciences Inc. received an updated ownership report from Commodore Capital. Commodore Capital LP and Commodore Capital Master LP filed Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 18,851 common shares, representing about 0.3% of Bright Minds’ outstanding common shares.
The filing states that Commodore Capital, as investment manager to Commodore Capital Master LP, may be deemed to beneficially own these securities, with shared voting and dispositive power over all reported shares. The ownership percentage is based on 7,635,789 common shares outstanding as of September 30, 2025.
The signatory certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Bright Minds Biosciences Inc., but instead under a passive investment intent consistent with Schedule 13G requirements.
Bright Minds Biosciences Inc. received an amended Schedule 13G showing that Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. jointly report beneficial ownership of 449,290 common shares, or 4.6% of the class. This percentage is based on 9,732,161 common shares outstanding as reported in a recent prospectus supplement. The filing states the securities are not held for the purpose of changing or influencing control of the company.
Bright Minds Biosciences reported a net loss of $7.6 million for the quarter ended December 31, 2025, compared with net income of $49,610 a year earlier, as it sharply increased research and development spending.
R&D expenses rose to $5.7 million from $1.0 million, driven by expanded clinical and preclinical work and higher share-based compensation. Despite the loss, the company held $89.0 million in cash and cash equivalents and working capital of $89.2 million, and raised $13.9 million via its at-the-market program during the quarter.
Subsequently, on January 9, 2026, Bright Minds completed a public offering of 1,945,000 common shares at US$90.00 per share for gross proceeds of about US$175.1 million, further strengthening its funding for ongoing and planned trials of lead epilepsy candidate BMB-101 and other 5-HT2 programs.